Found 39 articles for: "alopecia"
Evaluating Anti-Inflammatory Potential of Platelet-Rich Plasma in Scarring Alopecia: A Systematic Review
December 2024 | Volume 23 | Issue 12 | Original Article | 1076 | Copyright © December 2024
Scarring alopecia, also known as cicatricial alopecia, is a group of hair loss disorders characterized by inflammatory destruction of hair follicles, leading to hair loss and scar tissue formatio...
Read MoreEfficacy of Topical Finasteride 0.25% With Minoxidil 5% Versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia
November 2024 | Volume 23 | Issue 11 | Original Article | 1003 | Copyright © November 2024
Background: Androgenetic Alopecia (AGA) (male pattern hair loss) is the most common form of alopecia in men, affecting 30% of men by the age of 30 years and 50% by the age of 50 ...
Read MoreEvaluation of Pericardial Effusions in Alopecia Patients on Low-Dose Oral Minoxidil Therapy
September 2024 | Volume 23 | Issue 9 | Original Article | 725 | Copyright © September 2024
Background: Minoxidil is an anti-hypertensive vasodilator increasingly used off-label for the treatment of alopecia. It is associated with an increased risk of pericardial effusi...
Read MoreRuxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
May 2024 | Volume 23 | Issue 5 | Case Reports | 378 | Copyright © May 2024
Alopecia areata (AA) is a common autoimmune disorder. Although its pathogenesis is not fully understood, AA involves CD8 T cell-mediated destruction of the hair follicle. Several treatment option...
Read MoreMitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With Ovarian Cancer
April 2024 | Volume 23 | Issue 4 | Case Reports | e102 | Copyright © April 2024
Inflammatory alopecia is an increasingly reported side effect of targeted cancer therapies. Here we report one case of inflammatory alopecia secondary to mitogen-activated protein kinase kinase (...
Read MoreHighlighting the Link Between Lichen Planus Pigmentosus and Frontal Fibrosing Alopecia
March 2024 | Volume 23 | Issue 3 | Features | 196 | Copyright © March 2024
Survey of the Prices of Topical Compounded Medications for Alopecia in the Tri-State Area
March 2024 | Volume 23 | Issue 3 | Original Article | 168 | Copyright © March 2024
Background: Currently, there is only one topical medication approved by the U.S. Food and Drug Administration for alopecia, minoxidil 2.5% and 5%. With limited options, dermatolo...
Read MoreSurvey of Dermatology Practitioners' Opinions and Prescribing Habits of Oral Minoxidil for the Treatment of Androgenetic Alopecia
March 2024 | Volume 23 | Issue 3 | Original Article | 136 | Copyright © March 2024
Background: Utilization of low-dose oral minoxidil has increased in recent years in association with several clinical studies that have shown its efficacy in treating androgeneti...
Read MoreExamining the Uncertainties Surrounding Exosome Therapy in Androgenetic Alopecia: A Call for Evidence-Based Practice
March 2024 | Volume 23 | Issue 3 | Features | e86 | Copyright © March 2024
Hair loss, a pervasive and often distressing condition, affects a substantial number of individuals globally. Although conventional treatments such as hair transplantation, topicals, oral medicat...
Read MoreOral Minoxidil Media Coverage: The Impact on Patient Perceptions and Practitioner Approaches to Androgenetic Alopecia
January 2024 | Volume 23 | Issue 1 | Editorials | 1364 | Copyright © January 2024
Review of Baricitinib in the Treatment of Alopecia Areata
September 2023 | Volume 22 | Issue 9 | Original Article | 935 | Copyright © September 2023
Background: Alopecia areata (AA) is a debilitating autoimmune disease that results in non-scarring hair loss. Baricitinib is the Food and Drug Administration (FDA) approved treat...
Read MoreA Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia
September 2023 | Volume 22 | Issue 9 | Original Article | 905 | Copyright © September 2023
Androgenetic alopecia (AGA) is the most common cause of hair loss in men and has limited treatment options. Minoxidil is a common therapeutic option for AGA patients because of its availability. Plate...
Read MoreReview of Superficial Cryotherapy for the Treatment of Alopecia Areata
August 2023 | Volume 22 | Issue 8 | Original Article | 802 | Copyright © August 2023
Cryotherapy has recently been examined as a potential treatment for alopecia areata (AA). AA is classically managed with intralesional or systemic steroids but relapse rates among those with long...
Read MoreMinimizing Bias in Alopecia Diagnosis in Skin of Color Patients
July 2023 | Volume 22 | Issue 7 | Features | 703 | Copyright © July 2023
Alopecia is one of the most common dermatologic conditions affecting black patients, with a significantly negative impact on quality of life.1,2 Timely and accurate diagnosis is theref...
Read MoreReal-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia
June 2023 | Volume 22 | Issue 6 | Original Article | 559 | Copyright © June 2023
Pattern-type hair loss is a highly prevalent condition affecting the majority of men and women at some point in their lifetime. Although genetics and androgens are instrumental in the pathogenesi...
Read MoreDermal Hypersensitivity Reaction to Semaglutide: Two Case Reports
April 2023 | Volume 22 | Issue 4 | Case Reports | 413 | Copyright © April 2023
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic agents that work by inducing insulin secretion and inhibiting release of glucagon in a glucose-dependent manner. They...
Read MoreDupilumab Induced Hair Regrowth in Alopecia Totalis
April 2023 | Volume 22 | Issue 4 | Case Reports | 410 | Copyright © April 2023
Alopecia Areata (AA) is an autoimmune process that results in varying degrees of hair loss. Currently, there is no single treatment that has proven to be efficacious in a large cohort of patients...
Read MoreReversal of Stress-Associated Alopecia
March 2023 | Volume 22 | Issue 3 | Case Reports | 300 | Copyright © March 2023
Novel coronavirus SARS-CoV-2, designated as COVID-19 by the World Health Organization (WHO) on February 11, 2020, is one of the highly pathogenic β-coronaviruses that infects humans.1 ...
Read MoreUtilization Management Barriers Among Patients With Cicatricial Alopecia
March 2023 | Volume 22 | Issue 3 | Features | 312 | Copyright © March 2023
Citation: Rypka K, Pathoulas J, Wharton K, et al. Utilization management barriers among patients with cicatricial alopecia. J Drugs Dermatol. 2023;22(3):312-314. doi:10.36849/JDD.684...
Read MoreTopical Minoxidil Adherence in Patients With Alopecia
March 2023 | Volume 22 | Issue 3 | Original Article | 252 | Copyright © March 2023
Background: Non-adherence to topical minoxidil in alopecia patients is a barrier to efficacy. Understanding patient factors associated with adherence and non-adherence may provide act...
Read More© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
